A Phase 1, Randomized, Open‐Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects - Albrecht, Detlef; Iwashima, Mic; Dillon, Debbie; Harris, Stuart; Levy, Jeff (Headache, 2020)
Keywords: Absorption; Active control; Bioavailability; Confidence intervals; dihydroergotamine; dihydroergotamine mesylate; Dosage; Electrocardiography; Headache; intranasal; Liquid chromatography; Mass spectrometry; Mass spectroscopy; Mathematical analysis; Metabolites; Migraine; Nausea; Pain; Parameters; Pharmacokinetics; Pharmacology; Plasma; Plasma levels; Randomization; Research Submissions; Safety; Signs and symptoms; Variability; pharmacokinetics; intranasal; migraine; dihydroergotamine; dihydroergotamine mesylate